Pricing Log in Create free account

Monte Rosa Therapeutics, Inc. (GLUE) vs Solid Biosciences Inc. (SLDB)

Monte Rosa Therapeutics, Inc. and Solid Biosciences Inc. are both Biotechnology companies. Monte Rosa Therapeutics, Inc. and Solid Biosciences Inc. are of similar size ($795.5M and $781.3M). Solid Biosciences Inc. has the higher net margin (0.00% vs −186.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Monte Rosa Therapeutics, Inc. leads on 9 and Solid Biosciences Inc. on 5.

Valuation

Metric GLUE SLDB Biotechnology median
P/E n/m n/m 11.19
P/S 13.50 94.26 9.15
P/B 1.91 3.10 2.23
Price to free cash flow n/m n/m 26.14
EV/EBITDA n/m n/m 0.71
EV/Sales 5.29 63.21 8.65
Earnings yield (15.00%) (25.46%) (33.82%)
Free cash flow yield (18.36%) (18.88%) (23.58%)

Profitability

Metric GLUE SLDB Biotechnology median
Gross margin 100.00% 0.00% 68.27%
Operating margin (214.46%) 0.00% 0.00%
Net margin (186.24%) 0.00% 0.00%
Free cash flow margin (247.98%) 0.00% 0.00%
Return on equity (35.30%) (76.87%) (50.82%)
Return on assets (22.63%) (64.86%) (46.08%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GLUE SLDB Biotechnology median
Revenue growth (TTM) (61.26%) — 7.42%
EPS growth (last fiscal year) 53.06% 34.97% 29.86%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GLUE SLDB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.32 11.99 4.72
Net debt to EBITDA 8.22 1.05 1.01

Dividend

Metric GLUE SLDB Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric GLUE SLDB Biotechnology median
Market cap 795.54m 781.27m 176.65m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack